UK markets close in 1 hour 48 minutes
  • FTSE 100

    6,980.76
    -71.86 (-1.02%)
     
  • FTSE 250

    17,590.69
    +28.27 (+0.16%)
     
  • AIM

    815.07
    -0.37 (-0.05%)
     
  • GBP/EUR

    1.1424
    -0.0027 (-0.23%)
     
  • GBP/USD

    1.1251
    -0.0070 (-0.62%)
     
  • BTC-GBP

    17,916.04
    +102.90 (+0.58%)
     
  • CMC Crypto 200

    459.29
    -3.83 (-0.83%)
     
  • S&P 500

    3,791.98
    +8.70 (+0.23%)
     
  • DOW

    30,286.98
    +13.11 (+0.04%)
     
  • CRUDE OIL

    87.88
    +0.12 (+0.14%)
     
  • GOLD FUTURES

    1,723.10
    +2.30 (+0.13%)
     
  • NIKKEI 225

    27,311.30
    +190.77 (+0.70%)
     
  • HANG SENG

    18,012.15
    -75.82 (-0.42%)
     
  • DAX

    12,477.32
    -39.86 (-0.32%)
     
  • CAC 40

    5,940.56
    -44.90 (-0.75%)
     

Rheumatoid Arthritis Diagnosis Tests Global Market Report 2022: Increasing Obesity Levels Underpins Market Growth

·4-min read
Company Logo
Company Logo

Global Market for Rheumatoid Arthritis Diagnosis Tests

Global Market for Rheumatoid Arthritis Diagnosis Tests
Global Market for Rheumatoid Arthritis Diagnosis Tests

Dublin, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Diagnosis Tests - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Rheumatoid Arthritis Diagnosis Tests Market to Reach $766.7 Million by 2026

Amid the COVID-19 crisis, the global market for Rheumatoid Arthritis Diagnosis Tests estimated at US$629.9 Million in the year 2022, is projected to reach a revised size of US$766.7 Million by 2026, growing at a CAGR of 4.8% over the analysis period. Serology Tests, one of the segments analyzed in the report, is projected to grow at a 5.1% CAGR to reach US$561.3 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Monitoring Ra Treatment Efficiency Tests segment is readjusted to a revised 4% CAGR for the next 7-year period. This segment currently accounts for a 31.6% share of the global Rheumatoid Arthritis Diagnosis Tests market.

The U.S. Market is Estimated at $129.4 Million in 2022, While China is Forecast to Reach $113.5 Million by 2026
The Rheumatoid Arthritis Diagnosis Tests market in the U.S. is estimated at US$129.4 Million in the year 2022. The country currently accounts for a 20.66% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$113.5 Million in the year 2026 trailing a CAGR of 6.1% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR while Rest of European market (as defined in the study) will reach US$120.4 Million by the close of the analysis period.

Global demographic trends spell opportunities for the rheumatoid arthritis (RA) diagnostic tests market. One important trigger encouraging the expansion of the market is the expansion of the ageing population along with the enhanced prevalence of rheumatoid arthritis across the world.

It is acknowledged that prevalence of RA increases with age, and therefore rising aging population widens the demand for diagnosis tests as well as treatments for RA. Over the course of the next two decades, the proportion of 65+ individuals in the total population is expected to double in countries such as the US, UK and Australia.

As per the World Health Organization (WHO), total number of people aged 65-years and above is projected to grow from the existing 605 million to nearly 2 billion by the year 2050.

The growing aging population is therefore offering continuous opportunities for the autoimmune disease diagnostics market, as with advancing age the incidence of various autoimmune conditions such as RA increases, which results in rise in testing volumes translating to higher demand for testing techniques for RA. As RA is mostly common among the old people, and the geriatric population has been increasing recently, the opportunities in the global rheumatoid arthritis diagnosis test market are expected to be on the rise in the future.

Select Competitors (Total 65 Featured):

  • Abbott Diagnostics

  • Augurex Life Sciences Corp.

  • Beckman Coulter, Inc.

  • Bio Rad Laboratories Inc.

  • Exagen Inc.

  • F. Hoffmann-La Roche Ltd.

  • Genway Biotech, Inc.

  • Microdrop LLC (imaware)

  • Qiagen NV

  • Siemens Healthcare GmbH

  • Svar Life Science AB

  • Thermo Fisher Scientific Inc.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Rising Incidence of Rheumatoid Arthritis Propels the Demand for Rheumatoid Arthritis Diagnosis

  • Growing Aging Population to Drive the Demand for RA Diagnostic Tests

  • Increasing Use of Rapid Diagnosis Tests Platform

  • Investigational Biomarkers to Diagnose and Monitor RA

  • New Biomarker Tests to Drive the Market Growth

  • More Specific Biomarker Tests

  • Growing Demand for Multiple Tests

  • Repercussions of Sub Optimal Accuracy in RA Testing Drive the Need for Multiple Tests

  • Recent Advancements in Treatment Methods to Boost Market Growth

  • Uptrend in Healthcare Expenditure Drives Opportunities

  • Increase in Number of Hospitals & Diagnostics Centers Augurs Well for Market in Developing Regions

  • Increasing Obesity Levels Underpins Market Growth

  • Technological Advancements Widen the Capabilities of RA Arthritis Tests

  • A Few of the Recent Launches and Advancements

  • Rapid RA Diagnostic Tests for Obtaining Results in Minutes

  • imawareT Introduces At-Home Rheumatoid Arthritis Screening Test

  • Swedish Biotech Breaks Barrier to Diagnosis with Rheumatoid Arthritis Test

  • Scipher Medicine Ties Up with Ambry Genetics to Bring Precision Medicine Test for Rheumatoid Arthritis to Market

  • A New Blood Test Could to Predict Rheumatoid Arthritis

  • IPM Launches Innovative Program for Rheumatoid Arthritis

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/m5jrjl

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900